Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DHMRI and Metabolon Announce Strategic Partnership

Published: Wednesday, September 04, 2013
Last Updated: Wednesday, September 04, 2013
Bookmark and Share
Agreement to provide expanded metabolomics capabilities.

The David H. Murdock Research Institute (DHMRI) and Metabolon, Inc. have announced that they have entered into a strategic agreement to align metabolomics research services.

Metabolon is a pioneering leader in discovery metabolomics and specializes in rapidly assessing metabolism in biological samples to quickly identify prospective biomarkers and to understand metabolic effects of treatments, interventions, nutritionals, etc.

The agreement complements DHMRI’s mass spectrometry and NMR-based metabolomics services through access to Metabolon’s industry-leading high-throughput biomarker discovery and profiling platform which provides an extensive, untargeted, broad metabolite survey of more than 4000 biochemicals.

“This agreement leverages the strengths of our organizations to best serve DHMRI collaborators to understand metabolism and ultimately answer key research questions and deliver healthy food products for consumers. We have worked extensively in food science and nutrition and recognize that our combined resources are indeed complementary. DHMRI is a center of excellence in nutrition research and we are delighted to do our part to meet their growing needs,” says Chris Bernard, Senior Vice President of Sales & Marketing for Metabolon.

DHMRI is an established not-for-profit research institute that provides flexible, client-focused research services to academia, government and industry collaborators.

This agreement, consistent with the DHMRI’s collaborative approach to scientific inquiry, provides partners with additional resources for metabolomics.

Metabolon’s global metabolomic approach can pinpoint active pathways which can be further interrogated by targeted and or customized approaches offered by the DHMRI Metabolomics team.

“We are excited to broaden the breadth of services offered by the DHMRI to our collaborators. The benefits stemming from the collective knowledge of our organizations will be readily realized by researchers, companies and consumers,” said Steve Lommel, Ph.D., Interim President, David H. Murdock Research Institute.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Darin Leigh Joins Metabolon as Chief Commercial Officer
New role to lead commercial strategy for biomarker discovery, precision medicine, and diagnostics products and services.
Tuesday, July 07, 2015
Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!